PDTs Post-Pear: Investing in Healthcare AI’s Next Wave

The initial promise of prescription digital therapeutics (PDTs) was undeniable: software as a medical intervention, rigorously tested, FDA-cleared, and reimbursed like a drug. Yet, the past few years have seen a significant market restructuring, punctuated by high-profile commercialization struggles, most notably Pear Therapeutics’ bankruptcy. This upheaval has left many questioning the economic viability of software-as-a-prescription. For growth-stage investors and pharmaceutical strategic buyers, understanding the survival strategies of remaining platforms is paramount to identifying the true leaders in healthcare AI innovation. Currently, nearly twenty prescription digital therapeutics have received FDA clearance in the U.S..

The Post-Pear Field: Re-evaluating the PDT Model

Pear Therapeutics and Akili Interactive pioneered the prescription digital therapeutic pathway, demonstrating the feasibility of FDA clearance for digital interventions. Pear’s eventual bankruptcy, however, served as a stark reminder that regulatory clearance, while critical, is not synonymous with commercial success. The challenge was not clinical efficacy, but rather the arduous path to securing broad, standard formulary coverage and scalable reimbursement. The market intel suggests that the core issue lay in the disconnect between FDA clearance and established payment models, a gap that proved insurmountable for even well-funded first movers. For years, the lack of a clear CMS benefit category for PDTs historically made establishing coverage and coding structures particularly challenging, resulting in limited public and private payer coverage. However, the 2025 Physician Fee Schedule represented a turning point with the introduction of the first reimbursable codes for PDTs. For companies like Akili Interactive, the imperative has been to navigate this restructured field by focusing on strong clinical trial rigor and evolving coverage pathways. Akili’s EndeavorRx, for instance, a game-based digital therapeutic for ADHD, has faced the uphill battle of establishing novel reimbursement mechanisms in a system designed for pharmaceuticals and traditional medical devices. The Institute for Clinical and Economic Review (ICER) plays an important role here, evaluating the clinical effectiveness and value of new technologies, including PDTs, to inform payer decisions ICER evaluation reports on digital therapeutics. Their assessments often highlight the need for more real-world evidence and cost-effectiveness data to justify broad coverage.

Clinical Rigor Beyond FDA Clearance: The New Table Stakes

In the wake of early PDT commercialization challenges, the bar for clinical evidence has been raised. It is no longer sufficient to simply achieve 510(k) clearance or even De Novo classification. Investors are now scrutinizing the depth and breadth of clinical trials, demanding evidence that extends beyond initial efficacy studies to demonstrate long-term outcomes and real-world impact. This emphasis aligns with the broader trend toward real-world evidence (RWE) in healthcare, where data derived from electronic health records, registries, and claims supplements traditional randomized controlled trials (RCTs) to strengthen both regulatory submissions and payer narratives. For a PDT to achieve economic viability, its clinical evidence must be compelling enough to secure not just FDA clearance, but also favorable coverage policies from major payers. This often means demonstrating superiority or non-inferiority to existing treatments, or addressing significant unmet medical needs with clear, quantifiable benefits to patient outcomes and healthcare costs. Without a strong clinical value proposition articulated in terms payers understand, even the most innovative SaMD will struggle to gain traction. The concept of a “data moat” is particularly relevant here. Proprietary datasets that continuously improve AI model performance and are difficult to replicate can provide a significant competitive advantage, strengthening the clinical evidence base over time.

Coverage Pathways and Regulatory Positioning: The Commercial Crucible

The trajectory for prescription digital therapeutics hinges on their ability to secure broad, standard formulary coverage, not merely FDA clearance. This requires a sophisticated understanding of reimbursement pathways, including the nuances of CPT codes (Category I and III), and the potential for New Technology Add-On Payments (NTAP) in inpatient settings. The challenge is that many PDTs are novel, often lacking established CPT codes, forcing companies to pursue Category III codes (temporary codes for emerging technologies) before potentially graduating to Category I (permanent codes). This process is lengthy and fraught with uncertainty. Plus, the regulatory positioning of a PDT plays a critical role. Devices that achieve Breakthrough Device Designation, for instance, benefit from expedited FDA review and potentially faster NTAP eligibility, which can bridge the payment gap by providing additional reimbursement for hospitals using these innovative technologies. The market has learned that a strong Quality Management System (QMS) compliant with ISO 13485 is not merely a regulatory hurdle but a foundational element for trust and commercial scalability. Investors conducting technical due diligence will invariably check for such certifications, recognizing that a mature QMS signals a company’s readiness for widespread adoption and ongoing regulatory compliance. On top of that, adherence to Good Machine Learning Practice (GMLP) principles, as outlined by regulatory bodies, is becoming a key differentiator, signaling a commitment to safe, effective, and continuously improving AI/ML medical devices.

The Future of PDTs: A Focus on Enterprise Integration and Value

The market restructuring has underscored that successful PDTs must transcend the “point solution” mentality and integrate smoothly into existing healthcare workflows. This means addressing not only clinical efficacy but also implementation challenges, patient engagement, and demonstrable return on investment for healthcare systems. The concept of a “wedge product”, a narrow, focused offering used to gain initial market entry before expanding to adjacent use cases, is a viable strategy for PDTs seeking to establish a foothold and build trust within the healthcare ecosystem. For growth-stage investors, the focus has shifted from mere technological novelty to market survival metrics. This includes evaluating a company’s ability to navigate the complex patent thicket surrounding many digital health innovations, its commitment to strong cybersecurity and data privacy (HIPAA, HITRUST, SOC 2 compliance are non-negotiable), and its long-term strategy for algorithmic drift. The companies that will thrive are those that can demonstrate a clear path to sustainable revenue through established reimbursement channels, supported by compelling clinical and economic evidence Payer coverage policies for digital therapeutics. In conclusion, the trajectory for prescription digital therapeutics is one of maturation and consolidation. The initial exuberance has been tempered by the realities of commercialization, leading to a more discerning market. The companies that will lead the next wave of healthcare AI innovation are those that prioritize rigorous clinical validation, proactive engagement with payers to secure broad formulary coverage, and a deep understanding of the regulatory field. For investors, the opportunity lies in identifying those PDTs that have learned from the challenges of the past and are building truly economically viable solutions, not just technologically advanced ones.